Choice of radiotherapy modality for the combined treatment of non-small cell lung cancer with brain metastases: whole-brain radiation therapy with simultaneous integrated boost or stereotactic radiosurgery

Purpose To compare Whole-brain radiation therapy with simultaneous integrated boost (WBRT+SIB) to stereotactic radiosurgery (SRS)for non-small cell lung cancer (NSCLC)with brain metastases (BMs)in terms of overall survival (OS), intracranial progression-free-survival(iPFS), toxicity and objective response rate (ORR) Methods A retrospective review was performed in our hospital 90 patients diagnosed NSCLC- BM who received either SRS (n = 48) or WBRT+SIB 42) from January 2016 2022. 76 (84.44%) systemic drug after radiotherapy, including chemotherapy(n=53), targeted therapy(n=40), immunotherapy(n=23), anti-vascular therapy(n=45). OS iPFS were estimated by the Kaplan-Meier method compared using log-rank test. Univariate Multivariate analysis prognostic factors Cox proportional hazard regression model. Results The cohort had a longer median (20.0 versus (VS) 12.0 months, P 0.0069) similar (32.0 vs 28.0 0.195) than cohort. Intracranial rates WBRT +SIB cohorts 76.19% 70.09%, respectively (P 0.566). Disease control 88.09% 83.33%, 0.521). showed that is only factor affecting iPFS(hazard ratio (HR):0.597 {95%confidence interval(CI):0.370-0.966}, P=0.035). Sex, Liver metastasis Lymph node are risk for NSCLC-BM. Conclusion In context therapy, may have better local NSCLC-BM patients.